drugset
drugset / Trial / NCT02639026

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

NCT02639026 ↗

Phase 1 Completed 53 enrolled Abramson Cancer Center at Penn Medicine
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study is to determine how best to combine hypofractionated radiotherapy, MEDI4736, and tremelimumab and to determine how safe and tolerable hypofractionated radiotherapy, MEDI4736, and tremelimumab are when given together in subjects with metastatic, melanoma, non small cell lung cancer (NSCLC), breast cancer, and pancreatic cancer.

Timeline

Start
2016-01-26
Primary completion
2023-06-27
Completion
2023-06-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Durvalumab Monoclonal antibody 10 mg/kg —
Subject Tremelimumab Monoclonal antibody 1 mg/kg —

Indications

breast cancer malignant pancreatic neoplasm melanoma metastatic malignant neoplasm non-small cell lung carcinoma